Overview: Lactate Dehydrogenase (LDH) Marker Rapid TestIntroduction: The Lactate Dehydrogenase (LDH) Marker Rapid Test is a diagnostic tool designed to detect LDH levels in serum or plasma samples, facilitating the screening of tissue damage or cancer. Associated with conditions like myocardial infarction, hemolysis, or lymphoma, this metabolic disorder presents with fatigue, pain, and severe complications like organ failure if untreated, particularly in individuals with chronic disease or malignancy. Per the 2023 American Society of Clinical Oncology guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in oncology or emergency settings. This rapid diagnostic falls under biochemistry and targets individuals with systemic symptoms or cancer risk factors, addressing the challenge of early detection to guide chemotherapy or supportive care. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing complications. Its multi-sample capability enhances its utility.Other Names: LDH Rapid Test.FDA Status: FDA approved, CLIA certified for biochemistry, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Roche, this test advanced tissue marker detection, providing a rapid alternative to traditional assays.Purpose: The test screens for LDH to guide tissue damage or cancer diagnosis, assess metabolic status, and inform treatment and prevention strategies.Test Parameters: Presence of LDH, detected with reasonable specificity to indicate cellular damage, typically detectable in serum or plasma at elevated levels during active disease.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fatigue, pain, or recent trauma.Specimen: Serum 2-5 mL, Plasma 2-4 mL, collected using sterile SST or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on fatigue, pain, cancer history, or recent injury, as well as any family history of chronic disease or recent infections.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated conditions including organ failure, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent exercise can affect results. Correlation with imaging or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible tissue damage or cancer, necessitating further investigation like imaging or oncology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled during stable periods.Specialist Consultation: Oncologists or emergency physicians should be consulted for case management, treatment planning, and coordination with disease programs.Additional Supporting Tests: Imaging, biopsy, or troponin for confirmation.Test Limitations: The test may produce false positives in hemolysis or false negatives in early disease, requiring a comprehensive diagnostic approach that includes clinical correlation.References: ASCO Guidelines 2023, Journal of Oncology 2024, Biochemistry 2025.